According to the recommendations of Guidelines of Chinese Society of Clinical Oncology for NSCLC (2022 edition) (Guidelines Working Committee of Chinese Society of Clinical Oncology, 2022), PD-1/PD-L1 inhibitors in combination with chemotherapy is the major first-line treatment regimen for patients with advanced NSCLC without driver mutations, including pembrolizumab, atezolizumab, camrelizumab, and sugemalimab. The gene discussed is CD274; the disease is non-small cell lung carcinoma.